The Chemours Company CC logged profits of $52 million or 34 cents per share in first-quarter 2024, down from the year-ago quarter's profit of $145 million or 96 cents. Barring one-time items, earnings came in at 32 cents per share. It beat the Zacks Consensus Estimate of 25 cents. The company reported net sales of $1,350 million in the first quarter, down roughly 12% year over year. It fell short of the Zacks Consensus Estimate of $1,360.3 million. The downside was primarily attributed to a 23% decline in the Advanced Performance Materials unit, a 7% decrease in Titanium Technologies and an 8% fall in the Thermal & Specialized Solutions Segment. Volumes in the quarter fell 6% while price declined 5%. The Chemours Company Price, Consensus and EPS Surprise The Chemours Company Price, Consensus and EPS Surprise The Chemours Company price-consensus-eps-surprise-chart | The Chemours Company Quote Segment Highlights The Titanium Technologies division recorded revenues of $588 million in the quarter, marking a 7% decline compared to the previous year. This was below our estimate of $592.5 million. The downside was due to a 7% decline in price with volume and currency remaining relatively stable. In the Thermal & Specialized Solutions segment, revenues saw an 8% year-over-year decline, reaching $449 million in the reported quarter. It fell short of our estimate of $458.1 million. The downside was attributed to a 6% volume decrease and 2% price decline. Revenues in the Advanced Performance Materials unit amounted to $299 million, marking a decline of 23% year over year. It surpassed our estimate of $290 million. The decline was primarily driven by an 18% drop in volumes and a 5% decrease in pricing. Financials Chemours ended the quarter with cash and cash equivalents of $746 million, down around 9% year over year. Long-term debt was $3,968 million, up roughly 10% year over year. Cash used in operating activities was $290 million in the reported quarter. Outlook Moving ahead, CC expects Titanium Technologies to achieve sequential net sales growth of around 15% in the second quarter of 2024, reflecting the earlier communicated improvement in its TiO2 orderbook. Adjusted EBITDA growth is forecast to be in-line with the growth in net sales. Higher volumes and improved fixed cost absorption are projected to be partly offset by the shift in timing of higher-cost ore consumption, much of which is expected for the second quarter. For the second quarter, Chemours sees consolidated net sales to rise around 15% sequentially. Consolidated adjusted EBITDA is expected to increase roughly 15% on a sequential comparison basis. Price Performance Shares of Chemours are down 11.9% in the past year compared with the industry’s fall of 4.1%. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Key Picks Chemours currently carries a Zacks Rank #3 (Hold). Better-ranked stocks worth a look in the basic materials space include Gold Fields Limited GFI, sporting a Zacks Rank #1 (Strong Buy), and L.B. Foster Company FSTR and American Vanguard Corporation AVD, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for GFI’s first-quarter earnings is pegged at 22 cents per share. The consensus estimate for GFI’s first-quarter earnings has been stable in the past 60 days. L.B. Foster is slated to report first-quarter results on May 7. The consensus estimate for FSTR’s first-quarter earnings is pegged at a loss of 16 cents per share. The company’s shares have rallied 114.7% in the past year. American Vanguard is expected to report first-quarter results on May 14. The consensus estimate for AVD’ first-quarter earnings is pegged at 8 cents per share, indicating a year-over-year rise of 14.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gold Fields Limited (GFI):Free Stock Analysis Report L.B. Foster Company (FSTR):Free Stock Analysis Report American Vanguard Corporation (AVD):Free Stock Analysis Report The Chemours Company (CC):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q1
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...